INSIGHTS· Apr 2026
[ Sectors / Healthcare & Pharmaceutical ]
Healthcare and pharma companies face a convergence of ESG pressures: from pharmaceutical waste and Scope 3 supply chain emissions to patient access metrics and governance scrutiny from global institutional investors.
[ What's coming ]
ISSB S1/S2 · GRI 403 & 416 · EU CSRD · Pharmaceutical supply chain due diligence · NHS Net Zero Supply Chain requirements · Access to medicine frameworks · IFC Performance Standards
[ Services ]
Scope 1, 2 & 3 Emissions Baseline
Carbon measurement across manufacturing, cold chain logistics, medical waste and supply chains, built to GHG Protocol standards and buyer-ready.
Pharmaceutical Waste & Environmental Compliance
Waste management frameworks, effluent and hazardous material documentation: regulatory compliance and IFC Performance Standard alignment.
Access & Social Impact Measurement
Patient access, affordability and community health outcome metrics, for companies seeking impact investment or responding to ESG ratings on social performance.
ESG Reporting & Disclosure
ISSB and GRI-aligned sustainability reporting for listed pharma and healthcare companies facing investor and regulatory disclosure requirements.
Supply Chain Due Diligence
Supplier mapping, ethical sourcing and HRDD documentation across active ingredient and medical device supply chains.
DFI & Impact Investment Readiness
ESG governance and impact measurement frameworks for healthcare businesses accessing IFC, ADB or impact capital.
[ Who we work with ]
Pharmaceutical manufacturers · Hospital groups · Medical device companies · Healthcare holding companies · Health-focused impact investors
